- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05742204
Plasma proteomiske biomarkører til tidlig diagnose af lungekræft
Identifikation og funktionel verifikationsundersøgelse i plasmaproteomiske biomarkører til tidlig diagnose af lungekræft
We will identify plasma proteomics biomarkers for early diagnosis of lung cancer.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients and controls. Artificial intelligent (AI) assisted proteomics classifier will be developed for early diagnosis of lung cancer.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiesteder
-
-
China
-
Hangzhou, China, Kina, 310009
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Study group: Patients with suspected or confirmed diagnosis of lung cancer. Control group: Non-cancer subjects including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
Beskrivelse
Inclusion Criteria:
- CT screening results showed that the size of pulmonary nodules was more than 5mm
- No treatment related to pulmonary nodules/lung cancer (including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy, etc.)
- Complete clinical and imaging data
- Chest CT/ low-dose spiral CT reports can be provided in the last 3 months
- Voluntarily sign informed consent
Exclusion Criteria:
- There is a history of tumor
- Clinically uncontrolled active infections, such as acute pneumonia, tuberculosis, etc.
- Received any treatment related to pulmonary nodules, such as antibiotics and hormones, in the past 4 weeks
- Complicated with other tumors and serious diseases of the heart, liver, kidney, brain, blood and other systems
- Participated in other clinical trials within the last 3 months
- Combined with liver and kidney insufficiency, hypoproteinemia and other diseases affecting protein content
- You are pregnant or breastfeeding
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Lung cancer group
Patients age over 18, with confirmed diagnosis of lung cancer. |
Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients . Plasma samples of control subjects were collected. |
|
Control group
Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc. |
Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients . Plasma samples of control subjects were collected. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma proteomic biomarkers
Tidsramme: 1 month after surgery
|
Plasma proteomic biomarkers for detection of lung cancer |
1 month after surgery
|
|
Model or classifier performance
Tidsramme: 1 month after surgery
|
Artificial intelligent (AI) assisted proteomics classifier will be developed for early diagnosis of lung cancer; and model or classifier performance including AUC, sensitivity, specificity, and accuracy |
1 month after surgery
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Weilin Wang, 2nd Affiliated Hospital, School of Medicine, Zhejiang University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2022-1109
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .